As­traZeneca’s Imfinzi/treme­li­mum­ab com­bo fiz­zles again on lung can­cer

As­traZeneca has found an­oth­er trap door for its com­bi­na­tion of the PD-L1 check­point Imfinzi and its CT­LA-4 com­bi­na­tion drug treme­li­mum­ab.

The re­search team on ARC­TIC says the com­bo has failed on both pro­gres­sion-free sur­vival as well as over­all sur­vival, un­able to beat chemo stan­dard of care as a third-line ther­a­py for non-small cell lung can­cer.

The phar­ma gi­ant says it did de­tect a clin­i­cal­ly mean­ing­ful ef­fect for Imfinzi alone in this group, but didn’t pow­er the study to demon­strate sta­tis­ti­cal sig­nif­i­cance.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.